Printer Friendly

Circulating epithelial cells in patients with benign colon diseases.

During the past decade, researchers have developed ultrasensitive assays that allow the detection of circulating tumor cells (CTCs) [6] at the single-cell stage in the peripheral blood (1). Most of these assays [including the US Food and Drug Administration (FDA)-cleared CellSearch[R] system (Veridex/Johnson & Johnson) and the CTC chip] are based on the enrichment and subsequent identification of CTCs via the use of antibodies against epithelial markers [e.g., the transmembrane glycoprotein EpCAM (epithelial cell adhesion molecule), cytokeratins (CKs)] that are expressed on both normal and malignant epithelial cells (2). The specificity of this widely accepted approach is derived from the fact that blood cells usually lack detectable expression of epithelial markers because of their mesenchymal origin. It is unclear, however, whether trafficking of normal epithelial cells could occur in the blood circulation under certain circumstances, which might contribute to false-positive findings in current assays unless unambiguous criteria for the malignant nature of the marker-positive cells are used. Thus far, only 1 report has suggested the presence of circulating epithelial cells in some patients with benign adenomas (3 of 30 patients, 10%) or benign inflammatory diseases (4 of 34 patients, 12%) (3), suggesting that cells from nonmalignant colonic epithelium may also gain entry into the bloodstream in patients with benign bowel diseases. This reverse-transcription PCR-based study, however, included rather unspecific epithelial markers: mucins, which are frequently produced in blood cells (3), and CK20, which can also be detected in normal granulocytes (4).

In the present study, we enrolled 53 patients [20 (37.7%) women and 33 (62.3%) men, mean age, 56.7 years; range, 18 -84 years] with benign colon diseases, including diverticulosis, benign polyps, Crohn disease, ulcerative rectocolitis, colonic endometriosis, and others (Table 1) at the Gastrointestinal Surgery Department, Hospital Saint-Eloi, University Medical Centre, Montpellier, France. None of these patients had a history of solid cancer. Twenty-five healthy control individuals were tested in parallel. The bioethics committee approved the study protocol (biobank no. DC2008830), and all patients provided written informed consent. For the detection of epithelial cells in blood, we used 2 independent CTC assays, both of which are based on the use of CKs for detecting tumor cells. Currently, the CellSearch system is the only technology that has been cleared by the FDA for the detection of CTC in patients with metastatic breast, prostate, or colorectal cancer (5-10). This system is based on positive selection for CTCs with antibodies to EpCAM and the staining of EpCAM-positive cells for CKs with 4',6-diamidino-2-phenylindole and for CD45. Interestingly, isolation and detection of CTCs with immunomagnetic-enrichment methods is critically dependent on the EpCAM clone used (11). More recently, we introduced a new functional test, the epithelial immunospot (EPISPOT) assay, which allows the detection of only viable tumor cells (12-15). Leukocytes in the blood sample are depleted with a cocktail of antibodies (not only anti-CD45, but also anti-CD4, anti-CD8, and anti-CD19), and the [CD45.sup.-] cells are cultured ex vivo. Of this cell subpopulation, only CK19-releasing cells are considered CTCs (16, 17). Even when the first 5 mL of peripheral blood were not discarded, blood analyses of healthy controls previously demonstrated the specificity of both assays (7, 17, 18); however, data for age-matched controls with benign diseases were lacking.

Remarkably, we found circulating epithelial cells in our patient cohort with both the CellSearch system and the CK19-EPISPOT assay, but we found no positive events in the group of healthy volunteers. The diagnosis of positively testing patients was based on the detection of positive events according to the strict criteria defined by both technologies and after comparisons with internal positive controls. The CellSearch system detected CK-positive cells in the blood of 6 (11.3%) of 53 patients, and the CK19-EPISPOT assay found CK19-releasing cells in 10 (18.9%) of 53 patients. Only 1 sample was positive with both CTC assays (see Table 1 in the Data Supplement that accompanies the online version of this brief communication at These results demonstrate that the CellSearch and EPISPOT assays are complementary tools for detecting circulating epithelial cells, a not surprising result given the 2 different capture and detection technologies. Beyond the fact that these circulating cells were both EpCAM positive and pan-CK positive (CK8, CK18, CK19) (Fig. 1), their nuclear morphology was more consistent with a benign gland (Fig. 1, case 1). Concerning the CK19-EPISPOT assay, the fluorescent CK19 immunospots were comparable in size and fluorescence intensity to those obtained with the control HT-29 colon cancer cell line (Fig. 1, case 3). The number of positive cells ranged from 3 to 37 with the CellSearch system and from 1 to 41 with the CK19EPISPOT assay (see Fig. 1 in the online Data Supplement). The probability that these cells were rare blood cells ectopically expressing epithelial CKs is low, because CD45+ cells were excluded by either parallel immunostaining (CellSearch) or immunomagnetic depletion (EPISPOT assay). The numbers of CK-positive cells found in the patients with benign diseases with the 2 technologies were significantly lower than in the cancer group, which was used as a positive control in our study (see Fig. 1 in the online Data Supplement). Finally, after 3 years of follow-up, none of these patients have been diagnosed with colorectal cancer or another epithelial cancer. Of note is that both the CellSearch assay and the EPISPOT assay used in this study use CKs as markers to distinguish epithelial cells from leukocytes, but CKs are expressed in normal and malignant epithelial cells.


In conclusion, our analysis suggests that epithelial cells from nonmalignant colonic epithelium may enter the bloodstream under certain conditions, such as inflammation. This finding is consistent with the fact that inflammatory cytokines can stimulate the migration of epithelial cells (19). With respect to bowel diseases in particular, the potential background of nonmalignant epithelial cells in blood may be an important confounding factor in cancer patients with very low "CTC" counts and may lead to false-positive findings in CTC diagnostics unless strict morphologic criteria are applied. Unambiguous morphologic identification of each marker-positive cell in a given blood or bone marrow sample is difficult (20), however, and most cells detected in our study met the "tumor cell" criteria of the FDA-cleared CellSearch device.

We cannot exclude the possibility that some of the false-positive events detected in our study were actually tumor cells already present in some of the benign lesions or in the adjacent colon, even if such cells were not detected by endoscopic visual inspection and/or via routine histopathologic analysis of the resected samples. Because tumor cell dissemination appears to be an early event in tumor progression, CTCs may appear at very early stages of tumor development, and their detection may have potential for use in the early diagnosis of colon cancer. Large-scale epidemiologic studies with long-term follow-up are required to test this provocative hypothesis. Moreover, additional genetic characterization for mutations in oncogenes [e.g., KRAS [7] (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)] or tumor suppressor genes [e.g., TP53 (tumor protein p53)], and fluorescence in situ hybridization-based detection of numerical chromosomal aberrations at the single-cell level may add specificity to current CTC assays. Carcinoma cells are genetically heterogeneous, however, a fact that points to the need for complex technologies for multiplexing single CTCs. Moreover, hundreds of patients with benign disease need to be analyzed, because we assume that only a small fraction of CK-positive cells (if any at all) would be tumor cells, given that most of our patients with benign diseases have an excellent prognosis and will not develop cancer or metastasis. Thus, a large effort is required to prove the nature of circulating CK-positive cells in these patients, but the morphology of these cells suggests that most might not be CTC.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: Grant from the European Commission (DISMAL project, contract no. LSHC-CT-2005-018911); K. Pantel, European Research Council (ERC) Advanced Investigator Grant (no. 269081).

Expert Testimony: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

Acknowledgments: We are grateful to Nathalie Pfizster and Delphine Gueroult in Montpellier, as well as to Cornelia Coith and Oliver Mauermann in Hamburg, for their expert technical assistance.


(1.) Muller V, Alix-Panabieres C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010;46:1189-97.

(2.) Pantel K. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010;16:398-406.

(3.) Hardingham J, Hewett P, Sage R, Finch J, Nuttall J, Kotasek D, Dobrovic A. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 2000;89:8-13.

(4.) Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable backgro nd transcription in gran locytes. Br J Cancer 1999;81:870-3.

(5.) Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circ lating t mor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.

(6.) Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.

(7.) Riethdorf S, Fritsche H, Mueller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13: 920-8.

(8.) Cohen SJ, Punt CJ, lannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progressionfree survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:3213-21.

(9.) Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9.

(10.) Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008;19: 935-8.

(11.) Antolovic D, Galindo L, Carstens A, Rahbari N, Buchler MW, Weitz J, Koch M. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol 2010;10:35.

(12.) Alix-Panabieres C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005;299:177-88.

(13.) Alix-Panabieres C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 2005; 51:1538-41.

(14.) Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007;53: 537-9.

(15.) Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, Pantel K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15:1032-8.

(16.) Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008;14:5013-21.

(17.) Alix-Panabieres C, Vendrell JP, Slijper M, PelleO, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009;11:R39.

(18.) Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subject or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.

(19.) Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.

(20.) Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+CK+ CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010;21:1851-7.

Klaus Pantel, [1] Eric Deneve, [2] David Nocca, [2] Amandine Coffy, [3] Jean-Pierre Vendrell, [4] Thierry Maudelonde, [5] Sabine Riethdorf, [1] and Catherine AlixPanabieres [3, 4, 5] *

[1] Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [2] Department of Digestive Surgery, University Medical Centre, Saint-Eloi Hospital, Montpellier, France; [3] University Institute of Clinical Research UM1-EA2415-Epidemiology, Biostatistics and Public Health, Montpellier, France;[4] Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, University Medical Centre, Saint-Eloi Hospital, Montpellier, France; [5] Laboratory of Cell and Hormonal Biology, University Medical Centre, Arnaud de Villeneuve Hospital, Montpellier, France; * address correspondence to this author at: Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, Saint-Eloi Hospital, University Medical Centre, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5, France. Fax +33-467330113; e-mail

[6] Nonstandard abbreviations: CTC, circulating tumor cell; FDA, US Food and Drug Administration; EpCAM, epithelial cell adhesion molecule; CK, cytokeratin; EPISPOT, epithelial immunospot (assay).

[7] Human genes: KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; TP53, tumor protein p53.

Previously published online at DOI: 10.1373/clinchem.2011.175570
Table 1. Distribution of patients with benign colon diseases related
to the presence of CTCs and counts of CTCs detected by the EPISPOT
and CellSearch assays.

                                 EPISPOT assay      P

[CTC.sup.+] patient              52.5               0.37
  age, years (a)
[CTC.sup.+] patients,            10/53 (18.9)
  n/total (%) (b)
    Female                       3/20(15)           0.72
    Male                         7/33(21.2)
    Disease type                                    0.86
    Diverticulosis               5/23(21.7)
    Benign polyps                1/12 (8.3)
    Crohn disease                2/7 (28.6)
    Ulcerative rectocolitis      1/5 (20)
    Other                        1/6(18.7)
CTC count (c)
  Total                          2.4 (0-41), 0
  Per disease
    Diverticulosis               3.5 (0-41), 0
    Benign polyps                0.5 (0-6), 0
    Crohn disease                1 (0-6), 0
    Ulcerative rectocolitis      6.4 (0-32), 0
    Other                        0.4 (0-2), 0

                                 CellSearch assay   P

[CTC.sup.+] patient age,         65.8               0.13
  years (a)
[CTC.sup.+] patients,            6/53 (11.3)
  n/total (%) (b)
    Female                       2/20(10)           1.0
    Male                         4/33 (12.1)
    Disease type                                    1.0
    Diverticulosis               3/23 (13)
    Benign polyps                1/12 (8.3)
    Crohn disease                1/7 (14.3)
    Ulcerative rectocolitis      0/5 (0)
    Other                        1/6 (18.7)
CTC count (c)
  Total                          1.1 (0-37), 0
  Per disease
    Diverticulosis               2 (0-37), 0
    Benign polyps                0.2 (0-3), 0
    Crohn disease                0.8 (0-5), 0
    Ulcerative rectocolitis      0
    Other                        0.4 (0-3), 0

(a) Data are presented as the mean.

(b) Data are presented as the number of CTC+ patients/total number of
patients in the group (percent).

(c) Data are presented as the mean (range), median.
COPYRIGHT 2012 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Brief Communication
Author:Pantel, Klaus; Deneve, Eric; Nocca, David; Coffy, Amandine; Vendrell, Jean- Pierre; Maudelonde, Thie
Publication:Clinical Chemistry
Article Type:Report
Geographic Code:4EUFR
Date:May 1, 2012
Previous Article:Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: The Minnesota heart survey.
Next Article:Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters